Validity of a multiphase CT-based radiomics model in predicting the Leibovich risk groups for localized clear cell renal cell carcinoma: an exploratory study

[1] Ljungberg B(2022)European Association of Urology guidelines on renal cell carcinoma: the 2022 update Eur Urol 82 399-410

[2] Albiges L(2016)Renal cancer Lancet 387 894-906

[3] Abu-Ghanem Y(2018)Prognostic factors and prognostic models for renal cell carcinoma: a literature review World J Urol 36 1943-1952

[4] Capitanio U(2003)Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials Cancer 97 1663-1671

[5] Montorsi F(2022)External validation of the 2003 Leibovich prognostic score in patients randomly assigned to SORCE, an international phase III trial of adjuvant sorafenib in renal cell cancer J Clin Oncol 40 1772-1782

[6] Klatte T(2022)The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study Eur J Nucl Med Mol Imaging 49 2949-2959

[7] Rossi SH(2018)Imaging for the diagnosis and response assessment of renal tumours World J Urol 36 1927-1942

[8] Stewart GD(2020)Introduction to radiomics J Nucl Med 61 488-495

[9] Leibovich BC(2019)Radiomics: data are also images J Nucl Med 60 38S-44S

[10] Blute ML(2022)A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules EBioMedicine 86 104344-4089

[1] Ljungberg B(2022)European Association of Urology guidelines on renal cell carcinoma: the 2022 update Eur Urol 82 399-410

[2] Albiges L(2016)Renal cancer Lancet 387 894-906

[3] Abu-Ghanem Y(2018)Prognostic factors and prognostic models for renal cell carcinoma: a literature review World J Urol 36 1943-1952

[4] Capitanio U(2003)Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials Cancer 97 1663-1671

[5] Montorsi F(2022)External validation of the 2003 Leibovich prognostic score in patients randomly assigned to SORCE, an international phase III trial of adjuvant sorafenib in renal cell cancer J Clin Oncol 40 1772-1782

[6] Klatte T(2022)The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study Eur J Nucl Med Mol Imaging 49 2949-2959

[7] Rossi SH(2018)Imaging for the diagnosis and response assessment of renal tumours World J Urol 36 1927-1942

[8] Stewart GD(2020)Introduction to radiomics J Nucl Med 61 488-495

[9] Leibovich BC(2019)Radiomics: data are also images J Nucl Med 60 38S-44S

[10] Blute ML(2022)A radiomics-based decision support tool improves lung cancer diagnosis in combination with the Herder score in large lung nodules EBioMedicine 86 104344-4089